

Constance Delaugerre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/517610/publications.pdf>

Version: 2024-02-01

32
papers

1,443
citations

516710

16
h-index

454955

30
g-index

36
all docs

36
docs citations

36
times ranked

3737
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis B Virus-Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort. <i>Clinical Infectious Diseases</i> , 2022, 74, 1012-1021.	5.8	4
2	Impact of Fast SARS-CoV-2 Molecular Point-Of-Care Testing on Patients' Length of Stay in an Emergency Department. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	4
3	Prevalence and Incidence of Human Papillomavirus Infection in Men Having Sex With Men Enrolled in a Pre-exposure Prophylaxis Study: A Sub-study of the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales Intervention Préventive de l'Exposition aux Risques avec et pour les hommes Gays Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, 41-49.	5.8	8
4	SARS-CoV-2 induces human plasmacytoid dendritic cell diversification via UNC93B and IRAK4. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	107
5	Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1286-1293.	3.0	4
6	Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY). <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab085.	0.9	0
7	Subclinical and Clinical Outcomes in Patients Coinfected With HIV and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective, Longitudinal Cohort Study. <i>JMIR Research Protocols</i> , 2021, 10, e24731.	1.0	6
8	Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12300 Replate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 813-822.	9.1	17
9	Frequency of relapse and persistent cutaneous symptoms after a first episode of chilblain-like lesion during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e566-e568.	2.4	10
10	Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital. <i>Blood Cancer Journal</i> , 2021, 11, 129.	6.2	0
11	Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B. <i>Liver International</i> , 2021, 41, 2874-2884.	3.9	4
12	Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3009-3019.	3.0	4
13	Analysis of T-cell responses directed against the spike and/or membrane and/or nucleocapsid proteins in patients with chilblain-like lesions during the COVID-19 pandemic. <i>British Journal of Dermatology</i> , 2021, 185, 1242-1244.	1.5	5
14	Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak*. <i>British Journal of Dermatology</i> , 2021, 185, 1176-1185.	1.5	33
15	Surfaces and equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the emergency department at a university hospital. <i>International Journal of Hygiene and Environmental Health</i> , 2020, 230, 113600.	4.3	27
16	COVID-19-Related IgA Vasculitis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1952-1953.	5.6	48
17	Kinetics of Hepatitis B Core-Related Antigen and Anti-Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus-Hepatitis B Coinfection. <i>Journal of Infectious Diseases</i> , 2020, 221, 1826-1837.	4.0	8
18	No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. <i>Maladies Infectieuses</i> , 2020, 50, 384.	5.0	620

#	ARTICLE	IF	CITATIONS
19	HIV rapid screening tests and self-tests: Be aware of differences in performance and cautious of vendors. <i>EBioMedicine</i> , 2018, 37, 382-391.	6.1	9
20	Intensification with pegylated interferon during treatment with tenofovir in <sc>HIV</sc> hepatitis B virus co-infected patients. <i>Journal of Viral Hepatitis</i> , 2016, 23, 1017-1026.	2.0	10
21	Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. <i>Journal of Hepatology</i> , 2016, 65, 683-691.	3.7	84
22	Use of hepatitis B surface and antigen quantification during extensive treatment with tenofovir in patients co-infected with <sc>HIV</sc> <sc>HBV</sc>. <i>Liver International</i> , 2015, 35, 795-804.	3.9	24
23	Persistent viremia in human immunodeficiency virus/hepatitis B coinfecting patients undergoing long-term tenofovir: Virological and clinical implications. <i>Hepatology</i> , 2014, 60, 497-507.	7.3	66
24	Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Replate) <i>The</i> , 2014, 14, 459-467.	9.1	94
25	Effect of Tenofovir With and Without Interferon on Hepatitis D Virus Replication in HIV hepatitis B Virus hepatitis D Virus-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1535-1540.	1.1	26
26	Comparison of resistance mutation patterns in historical plasma <sc>HIV RNA</sc> genotypes with those in current proviral <sc>HIV DNA</sc> genotypes among extensively treated patients with suppressed replication. <i>HIV Medicine</i> , 2012, 13, 517-525.	2.2	52
27	Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study). <i>Journal of Clinical Virology</i> , 2010, 47, 248-252.	3.1	14
28	Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. <i>Aids</i> , 2010, 24, 2391-2395.	2.2	26
29	Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2934-2939.	3.2	52
30	Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone. <i>Antiviral Therapy</i> , 2009, 14, 93-97.	1.0	15
31	Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen. <i>Aids</i> , 2008, 22, 1809-1813.	2.2	24
32	Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients. <i>Aids</i> , 2007, 21, 1210-1213.	2.2	24